Thermo Fisher announced that emergency use authorization (EUA) has been granted for their TaqPath COVID-19 Fast PCR Combo Kit 2.0 and the TaqPath COVID-19 RNase P Combo Kit 2.0, designed with an innovative, multi-target assay design to compensate for current and future emerging SARS-CoV-2 mutations.
The TaqPath Fast PCR Combo Kit 2.0 utilizes a fast direct-to-PCR (bypassing RNA extraction) workflow from raw saliva, which provides increased speed from raw saliva samples to results in approximately 2 hours, to help reduce supplies, reagents, and personnel costs. The TaqPath RNase P Combo Kit 2.0 is designed with an approximate three-hour turnaround time and can detect SARS-CoV-2 from individuals suspected of COVID-19 by their health care provider, as well as from patients who are asymptomatic, when tested twice over 2 or 3 days with at least 24 hours (and no more than 36 hours) between tests.
To learn more visit Thermo Fisher.
